Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTK6 | Q13882 | 15/20 | 0.39 |
| ▸ | AURKB | Q96GD4 | 7/20 | 0.34 |
| ▸ | LCK | P06239 | 6/20 | 0.34 |
| ▸ | PARP1 | P09874 | 1/20 | 0.30 |
| ▸ | TTK | P33981 | 1/20 | 0.30 |
| ▸ | JAK2 | O60674 | 1/20 | 0.30 |
| ▸ | JAK1 | P23458 | 1/20 | 0.30 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.30 |
| ▸ | MAPKAPK5 | Q8IW41 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL32675702 | 1.00 | PTK6 (0.39) | PTK6AURKBLCKPARP1TTK | |
| Trifluoroacetic Acid SCHEMBL25176066 | 0.96 | PTK6 (0.37) | PTK6AURKBLCKTTK | |
| SCHEMBL24112613 | 0.96 | PTK6 (0.39) | PTK6AURKBLCKTTKJAK2 | |
| SCHEMBL24112644 | 0.96 | PTK6 (0.39) | PTK6AURKBLCKTTKTBK1 | |
| SCHEMBL32675710 | 0.96 | PTK6 (0.39) | PTK6AURKBLCKTTKTBK1 | |
| SCHEMBL24112643 | 0.95 | PTK6 (0.41) | PTK6AURKBLCKTTKMAPKAPK5 | |
| SCHEMBL32675688 | 0.95 | PTK6 (0.36) | PTK6AURKBLCK | |
| SCHEMBL24112415 | 0.95 | PTK6 (0.36) | PTK6AURKBLCK | |
| SCHEMBL24112491 | 0.94 | PTK6 (0.40) | PTK6AURKBLCKPARP1TTK | |
| SCHEMBL25451075 | 0.94 | PTK6 (0.47) | PTK6AURKBLCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230141600-A1 | IMIDAZOPYRAZINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2023-05-11 | — | — | US | disclosed |
| WO-2021249896-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2021-12-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230141600-A1 | IMIDAZOPYRAZINE DERIVATIVES | IKZF3, RRP15, IK | PTK6 925/4885AURKB 4161/4885LCK 1817/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.